Serge Saxonov, Chief Executive Officer of 10x Genomics, Inc. (NASDAQ:TXG), recently completed two distinct sales of company stock, totaling 28,893 shares of Class A Common Stock. These dispositions amounted to approximately $709,057 over the course of last week's trading activity.
The specific sale prices during these transactions ranged from a low of $24.4415 per share up to $24.7092 per share. For context, 10x Genomics stock currently trades at $25.53, positioning it close to its 52-week high of $26.45. This recent performance follows a notable 197% gain recorded over the past year.
Details of Recent Transactions
The first sale took place on May 22, 2026. On this date, Mr. Saxonov disposed of 18,175 shares at a price of $24.4415 per share. The stated purpose for selling these particular shares was to cover tax withholding obligations related to the vesting of restricted stock units.
A second transaction followed on May 26, 2026. During this period, an additional 10,718 shares were sold at a weighted average price of $24.7092 per share. Importantly, this second sale was structured pursuant to a Rule 10b5-1 trading plan that Mr. Saxonov had initially adopted on November 29, 2025. It should be noted that the shares in this specific transaction were executed across multiple trades with prices varying between $24.45 and $24.88.
Current Holdings and Valuation Context
Following these recent sales, Mr. Saxonov's direct holdings of 10x Genomics Class A Common Stock total 1,138,380 shares. His indirect stake is managed through various trusts where he serves as trustee. These include 27 shares held via the Andromeda Trust, 213,250 shares through the Y/S Descendants’ Trust, and 71,644 shares administered by the Y/S Pot Trust.
From an external valuation perspective, InvestingPro analysis suggests that the stock may be overvalued at its current price levels, assigning a Fair Value of $22.11 according to their metrics.
Market Signals and Analyst Commentary
The company has received positive attention from several industry observers. William Blair recently upgraded 10X Genomics to an